



2026 Complex General Surgical Oncology

All References



Below you will find the topics and references for the 2026 Complex General Surgical Oncology Continuous Certification Assessment. Diplomates are **not** expected or required to read all of these references before or during the assessment. Key References are marked with a yellow star ★.

Due to permission limitations, we can only provide direct full-text links for articles that are already open access; all other links will direct to PubMed.

To view full-text articles for **all** references before starting your assessment, please log in to the [surgeon portal](#), where links and PDFs will be freely available beginning **August 8, 2026**. Additionally, full-text links and PDFs for all Key and Additional References will be available directly within the exam platform while you take your assessment.

Breast – Approach to Regional Lymph Nodes Basins

- ★ [Matar-Ujvary R, Sevilimedu V, Morrow M. Are clinically node-negative patients with a positive preoperative axillary lymph node biopsy appropriate candidates for sentinel lymph node biopsy?. *Ann Surg Oncol*. 2025;32\(1\):92-97. doi:10.1245/s10434-024-16321-6](#)

Breast – Fibroadenoma

- ★ [Bishr MK, Humphreys A, Ahmed M, et al. Contemporary management of phyllodes tumours of the breast: recommendations from the UK Association of Breast Surgery. *Br J Surg*. 2025;112\(8\):znaf152. doi:10.1093/bjs/znaf152](#)
- [Mohan SC, Tseng J, Marumoto A, et al. Upstaging of fibroepithelial lesions: a single-institution experience. *Ann Surg Oncol*. 2022;29\(4\):2193-2199. doi:10.1245/s10434-021-10931-0](#)

Breast – Histologic Subtypes (Ductal, Lobular)

- ★ [Mouabbi JA, Hassan A, Lim B, Hortobagyi GN, Tripathy D, Layman RM. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. *Breast Cancer Res Treat*. 2022;193\(2\):253-264. doi:10.1007/s10549-022-06572-w](#)
- [von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. *N Engl J Med*. 2019;380\(7\):617-628. doi:10.1056/NEJMoa1814017](#)

Breast – In Situ (Intraductal) Cancer

- ★ [American College of Surgeons Clinical Research Program. Operative Standards for Cancer Surgery: Breast, Lung, Pancreas, Colon. Vol 1. Wolters Kluwer Health; 2015:16.](#)



2026 Complex General Surgical Oncology

All References



Breast – Phyllodes Tumors

- ★ [Del Calvo H, Wu Y, Lin HY, et al. Margin width and local recurrence in patients with phyllodes tumors of the breast. *Ann Surg Oncol*. 2024;31\(12\):8048-8056. doi:10.1245/s10434-024-15892-8](#)

Colorectal – Anal Canal Neoplasms

- ★ [Lian B, Guo J. Therapeutic approaches to mucosal melanoma. *Am Soc Clin Oncol Educ Book*. 2025;45\(3\):e4733858. doi:10.1200/EDBK-25-473858](#)
- ★ [Morris VK, Kennedy EB, Amin MA, et al. Systemic therapy for stage I-III anal squamous cell carcinoma: ASCO guideline. *J Clin Oncol*. 2025;43\(5\):605-615. doi:10.1200/JCO-24-02120](#)
- [D'Angelo SP, Larkin J, Sosman JA, et al. Efficacy and safety of nivolumab alone or in combination With ipilimumab in patients with mucosal melanoma: a pooled analysis. *J Clin Oncol*. 2017;35\(2\):226-235. doi:10.1200/JCO.2016.67.9258](#)
- ECOG-ACR1N Cancer Research Group. Anus Cancer EA2165: Nivolumab after Combined Modality Therapy in Treating Patients with High Risk Stage II-IIIB Anal Cancer. Published March 9, 2025. Accessed March 30, 2026. <https://ecog-acrin.org/clinical-trials/ea2165-anus-cancer/>
- [Lian B, Li Z, Wu N, et al. Phase II clinical trial of neoadjuvant anti-PD-1 \(toripalimab\) combined with axitinib in resectable mucosal melanoma. *Ann Oncol*. 2024;35\(2\):211-220. doi:10.1016/j.annonc.2023.10.793](#)

Colorectal – Squamous Cell Carcinoma

- ★ [Gross ND, Miller DM, Khushalani NI, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. *N Engl J Med*. 2022;387\(17\):1557-1568. doi:10.1056/NEJMoa2209813](#)
- ★ [Rischin D, Porceddu S, Day F, et al. Adjuvant cemiplimab or placebo in high-risk cutaneous squamous-cell carcinoma. *N Engl J Med*. 2025;393\(8\):774-785. doi:10.1056/NEJMoa2502449](#)

Cutaneous – Distant Metastasis

- ★ [Betof Warner A, Corrie PG, Hamid O. Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future. *Clin Cancer Res*. 2023;29\(10\):1835-1854. doi:10.1158/1078-0432.CCR-22-1922](#)
- ★ [Mullinax JE, Egger ME, McCarter M, et al. Surgical considerations for tumor tissue procurement to obtain tumor-infiltrating lymphocytes for adoptive cell therapy. *Cancer J*. 2022;28\(4\):285-293. doi:10.1097/PPO.0000000000000608](#)
- [Ascierto PA, Lipson EJ, Dummer R, et al. Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti-programmed death-1/programmed death ligand 1 therapy: results from the phase I/IIa RELATIVITY-020 trial. *J Clin Oncol*. 2023;41\(15\):2724-2735. doi:10.1200/JCO.22.02072](#)



2026 Complex General Surgical Oncology

All References



- [Rohaam MW, Borch TH, van den Berg JH, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. *N Engl J Med*. 2022;387\(23\):2113-2125. doi:10.1056/NEJMoa2210233](#)
- [Zhou L, Barros E Silva MJ, Hsiao E, et al. FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma. *J Immunother Cancer*. 2025;13\(3\):e011483. doi:10.1136/jitc-2025-011483](#)

Cutaneous – Primary

- ★ [Han D, Han G, Zhao X, et al. Clinicopathologic predictors of survival in patients with desmoplastic melanoma. *PLoS One*. 2015;10\(3\):e0119716. Published 2015 Mar 26. doi:10.1371/journal.pone.0119716](#)
- ★ [Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. *N Engl J Med*. 2023;388\(9\):813-823. doi:10.1056/NEJMoa2211437](#)
- [Blank CU, Lucas MW, Scolyer RA, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. *N Engl J Med*. 2024;391\(18\):1696-1708. doi:10.1056/NEJMoa2402604](#)
- [Han D, Zager JS, Yu D, et al. Desmoplastic melanoma: is there a role for sentinel lymph node biopsy?. *Ann Surg Oncol*. 2013;20\(7\):2345-2351. doi:10.1245/s10434-013-2883-z](#)
- [Seth R, Agarwala SS, Messersmith H, et al. Systemic therapy for melanoma: ASCO guideline update. *J Clin Oncol*. 2023;41\(30\):4794-4820. doi:10.1200/JCO.23.01136](#)
- [Zijlker LP, van der Burg SJC, Blank CU, et al. Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery. *Eur J Cancer*. 2023;185:131-138. doi:10.1016/j.ejca.2023.03.003](#)

Endocrine – Thyroid Carcinoma

- ★ [Adler GK, Stowasser M, Correa RR, et al. Primary aldosteronism: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2025;110\(9\):2453-2495. doi:10.1210/clinem/dgaf284](#)
- ★ [Shariq OA, Waguespack SG, Hamidi S, et al. Approach to the patient: hereditary medullary thyroid carcinoma. *J Clin Endocrinol Metab*. 2025;110\(9\):2685-2697. doi:10.1210/clinem/dgaf089](#)
- [Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. *Thyroid*. 2015;25\(6\):567-610. doi:10.1089/thy.2014.0335](#)

Health Equity/Disparities Groups/Bias

- ★ [Arrey EN, GoPaul D, Anderson D, Okoli J, McKenzie-Johnson T. Addressing breast cancer disparities: a comprehensive approach to health equity. *J Surg Oncol*. 2024;130\(7\):1483-1489. doi:10.1002/jso.28011](#)



2026 Complex General Surgical Oncology

All References



- ★ Korn AR, Walsh-Bailey C, Correa-Mendez M, et al. Social determinants of health and US cancer screening interventions: a systematic review. *CA Cancer J Clin.* 2023;73(5):461-479. doi:10.3322/caac.21801

Hepatopancreatobiliary – Biliary Tract Cancers

- ★ Di Martino M, Ielpo B, Cremona S, et al. Adequate lymphadenectomy and adjuvant capecitabine warrant survival benefit in gallbladder cancer. *Eur J Surg Oncol.* 2025;51(11):110318. doi:10.1016/j.ejso.2025.110318
- ★ Franssen S, Rousian M, Filipe WF, et al. Hepatic arterial infusion pump chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma-PUMP-2 trial. *J Clin Oncol.* 2026;44(6):455-465. doi:10.1200/JCO-25-00923
- ★ Olthof PB, Bouwense SAW, Bednarsch J, et al. Failure to rescue after resection of perihilar cholangiocarcinoma in an international multicenter cohort. *Ann Surg Oncol.* 2025;32(3):1762-1768. doi:10.1245/s10434-024-16293-7
- ★ Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. *Lancet Oncol.* 2019;20(5):663-673. doi:10.1016/S1470-2045(18)30915-X
- Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2023;401(10391):1853-1865. doi:10.1016/S0140-6736(23)00727-4
- Xiao H, Ji J, Li S, et al. Adjuvant chemoradiation and immunotherapy for extrahepatic cholangiocarcinoma and gallbladder cancer: a randomized clinical trial. *JAMA Oncol.* 2025;11(9):1021-1029. doi:10.1001/jamaoncol.2025.1926
- Yaqub S, Busund S, Smedman TM, et al. Liver transplantation for locally advanced non-resectable intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: early results from the TESLA trial. *Br J Surg.* 2025;112(3):znaf054. doi:10.1093/bjs/znaf054

Hepatopancreatobiliary – Focal Nodular Hyperplasia

- ★ Frenette C, Mendiratta-Lala M, Salgia R, Wong RJ, Sauer BG, Pillai A. ACG clinical guideline: focal liver lesions. *Am J Gastroenterol.* 2024;119(7):1235-1271. doi:10.14309/ajg.0000000000002857



2026 Complex General Surgical Oncology

All References



Hepatopancreatobiliary – Hepatocellular Carcinoma

- ★ [Aliseda D, Zozaya G, Martí-Cruchaga P, et al. The impact of portal hypertension assessment method on the outcomes of hepatocellular carcinoma resection: a meta-analysis of matched cohort and prospective studies. *Ann Surg.* 2024;280\(1\):46-55. doi:10.1097/SLA.0000000000006185](#)
- ★ [Sangro B, Kudo M, Erinjeri JP, et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma \(EMERALD-1\): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. *Lancet.* 2025;405\(10474\):216-232. doi:10.1016/S0140-6736\(24\)02551-0](#)
- [Boilève J, Guimas V, David A, Bailly C, Toucheffeu Y. Combining immune checkpoint inhibitors with loco-regional treatments in hepatocellular carcinoma: ready for prime time?. *Curr Oncol.* 2024;31\(6\):3199-3211. doi:10.3390/curroncol31060242](#)
- [Kudo M, Ren Z, Guo Y, et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma \(LEAP-012\): a multicentre, randomised, double-blind, phase 3 study. *Lancet.* 2025;405\(10474\):203-215. doi:10.1016/S0140-6736\(24\)02575-3](#)
- [Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma \(TACE 2\): a randomised placebo-controlled, double-blind, phase 3 trial. *Lancet Gastroenterol Hepatol.* 2017;2\(8\):565-575. doi:10.1016/S2468-1253\(17\)30156-5](#)

Hepatopancreatobiliary – Liver, Metastatic Cancer

- ★ [van der Lei S, Puijk RS, Dijkstra M, et al. Thermal ablation versus surgical resection of small-size colorectal liver metastases \(COLLISION\): an international, randomised, controlled, phase 3 non-inferiority trial. *Lancet Oncol.* 2025;26\(2\):187-199. doi:10.1016/S1470-2045\(24\)00660-0](#)

Hepatopancreatobiliary – Pancreas, Benign Lesions

- ★ [Ohtsuka T, Fernandez-Del Castillo C, Furukawa T, et al. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas. *Pancreatology.* 2024;24\(2\):255-270. doi:10.1016/j.pan.2023.12.009](#)
- ★ [Panizza A, Polanco PM, Boone BA, et al. Prospective, multi-institutional, real-time next-generation sequencing of pancreatic cyst fluid reveals diverse genomic alterations that improve the clinical management of pancreatic cysts. *Gastroenterology.* 2023;164\(1\):117-133.e7. doi:10.1053/j.gastro.2022.09.028](#)



2026 Complex General Surgical Oncology

All References



Hepatopancreatobiliary – Pancreas, Malignant

- ★ [Brozzetti S, Carati M, Sterpetti AV. Systematic review and meta-analysis of clinical outcomes after enucleation of pancreatic metastases from renal cell carcinoma. *Dig Surg*. 2023;40\(1-2\):9-20. doi:10.1159/000528823](#)
- ★ [Garnier J, Marchetti A, Campbell B, et al. Carbohydrate antigen 19-9 delta function for survival prediction in borderline pancreatic cancer. A PANC-PALS consortium international multicenter derivation and validation study. *Ann Surg*. Published online April 16, 2025. doi:10.1097/SLA.0000000000006735](#)
- ★ [Park W, Chawla A, O'Reilly EM. Pancreatic cancer: a review. *JAMA*. 2021;326\(9\):851-862. doi:10.1001/jama.2021.13027](#)
- ★ [Singh S, Halperin D, Myrehaug S, et al. \[177Lu\]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours \(NETTER-2\): an open-label, randomised, phase 3 study. *Lancet*. 2024;403\(10446\):2807-2817. doi:10.1016/S0140-6736\(24\)00701-3](#)
- ★ [Wattenberg MM, Asch D, Yu S, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. *Br J Cancer*. 2020;122\(3\):333-339. doi:10.1038/s41416-019-0582-7](#)
- [Aziz H, Kotla A, Abbey R, et al. Renal metastasis to the pancreas: a comprehensive review. *J Gastrointest Surg*. 2026;30\(4\):102347. doi:10.1016/j.gassur.2026.102347](#)
- [Kunz PL, Graham NT, Catalano PJ, et al. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors \(ECOG-ACRIN E2211\). *J Clin Oncol*. 2023;41\(7\):1359-1369. doi:10.1200/JCO.22.01013](#)
- [LaRose M, Manji GA, Bates SE. Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer. *Semin Oncol*. 2024;51\(1-2\):36-44. doi:10.1053/j.seminoncol.2023.11.001](#)
- [Roalsø MT, Lucocq J, Pandanaboyana S, Søreide K. Surgery for metastasis to the pancreas: systematic review of observational cohort studies. *HPB \(Oxford\)*. 2025;27\(10\):1290-1300. doi:10.1016/j.hpb.2025.07.003](#)
- [Tsai S, George B, Wittmann D, et al. Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer. *Ann Surg*. 2020;271\(4\):740-747. doi:10.1097/SLA.0000000000003049](#)



2026 Complex General Surgical Oncology

All References



Sarcoma – Gastrointestinal Stromal Tumors

- ★ [Gronchi A, Bonvalot S, Poveda Velasco A, et al. Quality of surgery and outcome in localized gastrointestinal stromal tumors treated within an international intergroup randomized clinical trial of adjuvant imatinib. *JAMA Surg.* 2020;155\(6\):e200397. doi:10.1001/jamasurg.2020.0397](#)
- ★ [Honda M, Hiki N, Nunobe S, et al. Long-term and surgical outcomes of laparoscopic surgery for gastric gastrointestinal stromal tumors. *Surg Endosc.* 2014;28\(8\):2317-2322. doi:10.1007/s00464-014-3459-0](#)
- ★ [Mazer L, Worth P, Visser B. Minimally invasive options for gastrointestinal stromal tumors of the stomach. *Surg Endosc.* 2021;35\(3\):1324-1330. doi:10.1007/s00464-020-07510-x](#)
- ★ [Mueller CL, Braun J, Leimanis ML, Mouhanna J, Feldman LS, Ferri LE. Application of an individualized operative strategy for wedge resection of gastric gastrointestinal stromal tumors: effectiveness for tumors in difficult locations. *Surgery.* 2016;160\(4\):1038-1048. doi:10.1016/j.surg.2016.06.004](#)

Sarcoma – Retroperitoneal

- ★ [Gronchi A, Iadecola S, Restrepo-López J, et al. Early recurrence and prognosis in patients undergoing resection of primary retroperitoneal sarcoma: an international, retrospective cohort study. *EClinicalMedicine.* 2026;92:103778. doi:10.1016/j.eclinm.2026.103778](#)
- ★ [Lambdin J, Ryan C, Gregory S, et al. A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with high-risk retroperitoneal sarcoma \(STRASS2\). *Ann Surg Oncol.* 2023;30\(8\):4573-4575. doi:10.1245/s10434-023-13500-9](#)
- ★ [Danieli M, Swallow CJ, Gronchi A. How to treat liposarcomas located in retroperitoneum. *Eur J Surg Oncol.* 2023;49\(6\):1068-1080. doi:10.1016/j.ejso.2022.04.020](#)
- ★ [Snow H, Fiore M, Xie J, et al. Global variations in patterns of care for retroperitoneal sarcoma. *Ann Surg.* Published online June 16, 2025. doi:10.1097/SLA.0000000000006791](#)
- ★ [Tirota F, Fiore M, Bonvalot S, et al. Defining benchmark values for outcomes of comprehensive resection of primary retroperitoneal liposarcoma: a retrospective multicenter study. *EClinicalMedicine.* 2025;84:103280. doi:10.1016/j.eclinm.2025.103280](#)

Sarcoma – Truncal/Extremity

- ★ [Kasper B, Baldini EH, Bonvalot S, et al. Current management of desmoid tumors: a review. *JAMA Oncol.* 2024;10\(8\):1121-1128. doi:10.1001/jamaoncol.2024.1805](#)
- ★ [Mowery YM, Ballman KV, Hong AM, et al. Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity \(SU2C-SARC032\): an open-label, randomised clinical trial. *Lancet.* 2024;404\(10467\):2053-2064. doi:10.1016/S0140-6736\(24\)01812-9](#)



2026 Complex General Surgical Oncology

All References



Systems-Based Practice

- ★ [Ludwig KK, Kong A, Grossi S, Joseph KA, Cox S, Pratt D. Implementation of quality improvement projects: a practical guide from the American Society of Breast Surgeons Patient Safety and Quality Committee. *Ann Surg Oncol*. 2026;33\(2\):1221-1231. doi:10.1245/s10434-025-18609-7](#)
- [Temple LKF, Pusic AL, Liu JB, et al. Patient-reported outcome measures within a national multispecialty surgical quality improvement program. *JAMA Surg*. 2024;159\(9\):1030-1039. doi:10.1001/jamasurg.2024.1757](#)

Upper Gastrointestinal – Gastroesophageal Junction Cancer

- ★ [Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. *N Engl J Med*. 2025;393\(3\):217-230. doi:10.1056/NEJMoa2503701](#)
- [Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma \(FLOT4\): a randomised, phase 2/3 trial. *Lancet*. 2019;393\(10184\):1948-1957. doi:10.1016/S0140-6736\(18\)32557-1](#)
- [Hoepfner J, Brunner T, Schmoor C, et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. *N Engl J Med*. 2025;392\(4\):323-335. doi:10.1056/NEJMoa2409408](#)